Excreted Unchanged %
10-20
Half-Life (Normalesrd) Hours
1.8/2
Plasma Protein Binding %
60
Volume Of Distribution L/Kg
No data
Dose For Normal Renal Function
800 mg q8h
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
No data: 100% [D]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
No data: 100% [D]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
No data: 100% [D]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: No adjustment necessary, [B]
Supplement For Dialysis [Recommendation Level]: Pd
PD: No data: Dose for GFR <10
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: 100%, [D]
References
Balani SK, Woolf EJ, Hoagland VL, Sturgill MG, Deutsch PJ, Yeh KC, et al. Disposition of indinavir, a potent HIV-1 protease inhibitor, after an oral dose in humans. Drug Metab Dispos. 1996; 24: 1389-94. [PMID: 8971147] / Izzedine H, Aymard G, Hamani A, Launay-Vacher V, Deray G. Indinavir pharmacokinetics in haemodialysis [Letter]. Nephrol Dial Transplant. 2000; 15: 1102-3. [PMID: 10862669]
Toxicity Notes
Nephrolithiasis; acute renal failure due to crystalluria, tubulointerstitial nephritis. Minimal clearance with HD.